

Supplemental Table S2. Clinical Characteristics of Patients According to the Response for the 2nd RAI Therapy

Characteristic	Total (n=230)	Remission (n=152)	Persistent (n=78)	P value
Age at second RAI therapy, yr	41±13	41±12	42±15	0.420
Female sex	131 (57)	88 (58)	43 (55)	0.779
Time from diagnosis to 2nd RAI therapy, yr	6±5	6±5	6±5	0.466
Time interval between 1st and 2nd RAI therapies, mo	10±11	12±12	8±7	0.002
Goiter size, g (n=217) ^a				
<60	79 (36)	56 (38)	23 (33)	0.001
60–90	67 (34)	58 (40)	15 (21)	
≥90	63 (30)	33 (22)	32 (46)	
ATD discontinuation for ≥2 months ^b	70 (30)	54 (36)	16 (21)	0.023
Mean dosage of ATD ^b , mg	13±7	12±7	14±7	0.023
Pre-RAI TSH, μIU/mL (n=222) ^a	1.07±6.85	1.58±8.43	0.10±0.25	0.036
Pre-RAI free T4, ng/dL (n=222) ^a	2.47±1.64	2.25±1.25	2.89±2.14	0.016
Pre-RAI TSHR antibody, % (n=184) ^a	71±42	66±23	78±61	0.059
48-hr RAIU, %	52±19	51±20	52±18	0.643

Values are expressed as mean±standard deviation or number (%). *P* values were calculated from Student *t* test or chi-square test between the remission and the persistent group.

RAI, radioactive iodine; ATD, antithyroid drug; TSH, thyrotropin; T4, thyroxine; TSHR, TSH receptor; RAIU, radioactive iodine uptake.

^aThe analysis was performed only in patients with the available data; ^bDuring 6 months after first RAI therapy.